From Tolerx, After a Decade and $150M, Eagerly Awaits Data from Big Diabetes Trial:

dringler

dringler—

Doug Ringler is CEO of Cambridge, MA-based Tolerx.

Underwriters and Partners

Xconomy Insight

Sponsored · Special Report
As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future
Hyperinflation in rents is over
Hughes Marino

Sponsored · Video
The Bay Area and Beyond: Biocom Talks Innovation and COVID
A Fireside Chat with Biocom President & CEO Joe Panetta
Biocom

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Xconomy on Demand

We offer a number of ways to subscribe for free!